P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1K
12-okt, 9:49:20 (GMT+8) · SGD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoP8A tikeri uchun statistika yaratilmoqda...
Bozor kapitali
32,37 mln
Oʻrtacha hajm
1,32 ming
Hajmi
0,00
52 haftalik eng yuqori
0,26 SGD
52 haftalik eng past
0,10 SGD
Aksiya boʻyicha daromad
-0,04 SGD
Muomaladagi aksiyalar
267,53 mln
Xodimlar soni
111
Bozor kapitali
32,37 mln
Oʻrtacha hajm
1,32 ming
Hajmi
0,00
52 haftalik eng yuqori
0,26 SGD
52 haftalik eng past
0,10 SGD
Aksiya boʻyicha daromad
-0,04 SGD
Muomaladagi aksiyalar
267,53 mln
Xodimlar soni
111
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
AskTraders.com
·
37 daqiqa oldin
S&P 500 Can Absorb Fed Hikes, Says UBS CIO After Hot US Inflation
Foreign Policy Journal
·
1 soat oldin
Rigetti Computing (NASDAQ: RGTI) Stock Drops 21% In A Month As Quantum Sector Faces Commercialization Pressure
Traders Union
·
58 daqiqa oldin
Peter Tuchman: Nasdaq posts worst week since April 2025 tariff selloff as S&P 500 loses $1.3 trillion
Yahoo Finance
·
10 soat oldin
Michael Burry Warns of a Stock Market ‘Supervolcano’
Profil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Cordlife Group Ltd haqida
CEOYiu Pang Fai
Xodimlar soni111
Asos solingan2-may, 2001
Bosh ofislar-
SektorHealth care provider
Veb-saytcordlife.com